Indole hydrazide compound ZJQ-24 inhibits angiogenesis and induces apoptosis cell death through abrogation of AKT/mTOR pathway in hepatocellular carcinoma
Open Access
- 28 October 2020
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (10) , 1-13
Abstract
Angiogenesis and the activation of AKT/mTOR pathway are crucial for hepatocarcinoma development and progression, the activation of mTORC1/2 and relevant substrates have been confirmed in clinical hepatocarcinoma samples. Therefore, AKT/mTOR pathway represents the major targets for anti-cancer drugs development. Here, we investigated the anti-proliferative activity and mechanisms of ZJQ-24 in hepatocellular carcinoma, both in vivo and in vitro. A hepatocellular carcinoma xenograft model showed that ZJQ-24 significantly inhibited tumor growth with few side effects. MTT assays, flow cytometric analysis, Western blotting and immunohistochemistry identified that ZJQ-24 effectively suppressed hepatocellular carcinoma cell proliferation via G2/M phase arrest and caspase-dependent apoptosis but had no cytotoxic on normal cells. Furthermore, ZJQ-24 significantly blocked AKT/mTOR signaling by down-regulation of mTORC1 molecules, including phospho-p70S6K (Thr389) and phospho-4EBP-1 (Ser65, Thr37/46, Thr70) and phospho-AKT (Ser473) in HCC cells. It is very important that the ZJQ-24 did not induce the mTORC1-depdent PI3K/Akt feedback activation through JNK excitation. Moreover, ZJQ-24 inhibited the cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex. Immunohistochemistry further confirmed ZJQ-24 inhibited the tumor growth through suppression of VEGF and AKT/mTOR pathways in vivo. Thus, the present study is the first to illustrate that ZJQ-24 triggers antiangiogenic activity and apoptosis via inhibiting the AKT/mTOR pathway in hepatocellular carcinoma cells, providing basic scientific evidence that ZJQ-24 shows great potential function as inhibitor of angiogenesis and tumor growth in hepatocellular carcinoma.Keywords
Funding Information
- Natural Science Foundation of Yunnan Province (2018FB148)
This publication has 45 references indexed in Scilit:
- AKT as locus of cancer angiogenic robustness and fragilityJournal of Cellular Physiology, 2012
- Anti-oncogenic potential of the eIF4E-binding proteinsOncogene, 2012
- Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1α, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular CarcinomaClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Regulation of Eukaryotic Initiation Factor 4E (eIF4E) Phosphorylation by Mitogen-Activated Protein Kinase Occurs through Modulation of Mnk1-eIF4G InteractionMolecular and Cellular Biology, 2010
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJournal of Clinical Investigation, 2008
- Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanismOncogene, 2006
- IRS-1: Auditing the effectiveness of mTOR inhibitorsCancer Cell, 2006